Literature DB >> 12685629

Similar diagnostic performance for neurocysticercosis of three glycoprotein preparations from Taenia solium metacestodes.

Guido E Villota1, Diana I Gomez, Michel Volcy, Andrés F Franco, Edgar A Cardona, Rodrigo Isaza, Fernando Sanzón, Judy M Teale, Blanca I Restrepo.   

Abstract

The detection of antibodies to Taenia solium metacestodes is very important in the differential diagnosis of neurocysticercosis (NCC). In this study, an electroimmunotransfer blot (EITB) assay that uses an elaborate protocol with metacestode glycoproteins as antigens was compared with two other Western blots that use glycoproteins obtained using simpler methods, including an eluate from a lectin column, or the vesicular fluid (VF) of the parasite. The concordance between the three assays was 91% in patients with active NCC and 100% in patients with suspected NCC and previous documentation of negative serology. The specificities for the Western blots and the EITB assay were 98% and 100%, respectively (98% concordance). These data suggest that the simplest of these immunoassays, the one that uses the VF of T. solium metacestodes in a Western blot format, can be reliably used for the serologic diagnosis of NCC in developing countries where access to the EITB assay is difficult.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12685629

Source DB:  PubMed          Journal:  Am J Trop Med Hyg        ISSN: 0002-9637            Impact factor:   2.345


  2 in total

1.  Increased accumulation of regulatory granulocytic myeloid cells in mannose receptor C type 1-deficient mice correlates with protection in a mouse model of neurocysticercosis.

Authors:  Pramod Kumar Mishra; Elizabeth G Morris; Jenny A Garcia; Astrid E Cardona; Judy M Teale
Journal:  Infect Immun       Date:  2013-01-14       Impact factor: 3.441

2.  Banding pattern indicative of echinococcosis in a commercial cysticercosis Western blot.

Authors:  Dennis Tappe; B Grüner; P Kern; M Frosch
Journal:  Eur J Med Res       Date:  2009-09-28       Impact factor: 2.175

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.